Home > Publications database > Normo- or Hypo-Fractionated Photon or Proton Radiotherapy in the Management of Locally Advanced Unresectable Pancreatic Cancer: A Systematic Review. > print

001     278406
005     20240229162352.0
024 7 _ |2 doi
|a 10.3390/cancers15153771
024 7 _ |2 pmid
|a pmid:37568587
024 7 _ |2 pmc
|a pmc:PMC10416887
037 _ _ |a DKFZ-2023-01640
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Elkhamisy, Sally A
|b 0
245 _ _ |a Normo- or Hypo-Fractionated Photon or Proton Radiotherapy in the Management of Locally Advanced Unresectable Pancreatic Cancer: A Systematic Review.
260 _ _ |a Basel
|b MDPI
|c 2023
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1692010908_20940
|x Review Article
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a LAPC is associated with a poor prognosis and requires a multimodal treatment approach. However, the role of radiation therapy in LAPC treatment remains controversial. This systematic review aimed to explore the role of proton and photon therapy, with varying radiation techniques and fractionation, in treatment outcomes and their respective toxicity profiles.Clinical studies published from 2012 to 2022 were systematically reviewed using PubMed, MEDLINE (via PubMed) and Cochrane databases. Different radiotherapy-related data were extracted and analyzed.A total of 31 studies matched the inclusion criteria. Acute toxicity was less remarkable in stereotactic body radiotherapy (SBRT) compared to conventionally fractionated radiotherapy (CFRT), while in proton beam therapy (PBT) grade 3 or higher acute toxicity was observed more commonly with doses of 67.5 Gy (RBE) or higher. Late toxicity was not reported in most studies; therefore, comparison between groups was not possible. The range of median overall survival (OS) for the CFRT and SBRT groups was 9.3-22.9 months and 8.5-20 months, respectively. For the PBT group, the range of median OS was 18.4-22.3 months.CFRT and SBRT showed comparable survival outcomes with a more favorable acute toxicity profile for SBRT. PBT is a promising new treatment modality; however, additional clinical studies are needed to support its efficacy and safety.
536 _ _ |0 G:(DE-HGF)POF4-899
|a 899 - ohne Topic (POF4-899)
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |2 Other
|a SBRT
650 _ 7 |2 Other
|a locally advanced pancreatic adenocarcinoma
650 _ 7 |2 Other
|a photon therapy
650 _ 7 |2 Other
|a proton beam therapy
650 _ 7 |2 Other
|a systematic review
700 1 _ |a Valentini, Chiara
|b 1
700 1 _ |a Lattermann, Annika
|b 2
700 1 _ |a Radhakrishna, Ganesh
|b 3
700 1 _ |a Künzel, Luise A
|b 4
700 1 _ |0 0000-0002-7017-3738
|a Löck, Steffen
|b 5
700 1 _ |0 P:(DE-He78)91d4b4a1e36e2bec6c08ac43e6820834
|a Troost, Esther G C
|b 6
|u dkfz
773 _ _ |0 PERI:(DE-600)2527080-1
|a 10.3390/cancers15153771
|g Vol. 15, no. 15, p. 3771 -
|n 15
|p 3771
|t Cancers
|v 15
|x 2072-6694
|y 2023
909 C O |o oai:inrepo02.dkfz.de:278406
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 0000-0002-7017-3738
|a Deutsches Krebsforschungszentrum
|b 5
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)91d4b4a1e36e2bec6c08ac43e6820834
|a Deutsches Krebsforschungszentrum
|b 6
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF4-899
|1 G:(DE-HGF)POF4-890
|2 G:(DE-HGF)POF4-800
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|v ohne Topic
|x 0
914 1 _ |y 2023
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-01-24T07:56:58Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-30
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-30
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK Koordinierungsstelle Dresden
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21